Abstract

AbCellera Biologics will report fiscal second-quarter 2026 results on August 05, 2026 Post Market; this preview summarizes consensus and company guidance on revenue, margins, net income, and EPS alongside key business drivers and risks.

Market Forecast

Consensus for the quarter points to revenue of 7.78 million US dollars, an estimated year-over-year growth of 27.21%, with EBIT at approximately -51.81 million and EPS at -0.14, implying continued negative net income and compressed profitability. Specific forecasts for gross profit margin and net profit margin are not available; however, expectations imply losses narrow year over year alongside modest revenue growth. The company’s discovery partnerships are expected to be the core revenue engine this quarter, supported by research fees and milestone/licensing contributions. Platform-enabled discovery services remain the most promising segment, with estimated revenue of 7.78 million US dollars and a 27.21% year-over-year increase, while licensing revenue is expected to be small.

Last Quarter Review

In the prior quarter, AbCellera Biologics recorded revenue of 8.32 million US dollars, a GAAP net loss attributable to shareholders of 43.17 million US dollars, and unavailable gross and net profit margins; adjusted EPS was -0.14 and grew 6.67% year over year. Operating performance improved versus expectations, with revenue exceeding consensus and losses coming in narrower than feared. Main business mix tilted toward research fees at 8.12 million US dollars, with licensing at 0.19 million, highlighting the dependence on discovery contracts and the lumpy nature of milestone revenue.

Current Quarter Outlook

Discovery Partnerships and Research Fees

The discovery partnerships and associated research fees continue to anchor quarterly revenue. The forecast revenue of 7.78 million US dollars suggests sequential softness from the preceding quarter’s 8.32 million, consistent with milestone timing effects. Management focus on advancing partnered programs into later stages is a swing factor for near-term revenue recognition. With EPS projected at -0.14, cost discipline and the pace of R&D activity will be central to the trajectory of operating losses through the second half.

Licensing and Milestone Income

Licensing and milestone income remains the most volatile line and the potential upside lever for the print. The revenue composition last quarter skewed almost entirely to research fees, leaving room for positive surprise should any milestone events be recognized in the current period. Absent such events, the model implies limited contribution from licenses, keeping overall revenue near the guided run-rate and maintaining negative EBIT around -51.81 million.

Cash Burn, Operating Efficiency, and Pipeline Progress

The projected EBIT loss implies continued cash burn, and investor attention will likely center on operating efficiency initiatives. Updates on partnered asset progress, including any clinical entries or expansions, could shift sentiment even without immediate revenue impact. Any indication of increased partner activity or new agreements can improve forward visibility and justify expectations for gradual top-line growth.

Analyst Opinions

Analyst commentary over the last six months has tilted cautiously positive, emphasizing the company’s extensive partnership base and optionality for milestone upside while acknowledging near-term revenue variability and ongoing losses. The majority view leans constructive on medium-term prospects given the breadth of discovery programs and the potential for licensing income to scale as assets advance; a minority of views remain concerned about the timing of monetization and sustained operating losses. Overall, the balance of opinions suggests upside skew is contingent on execution in discovery programs and selective milestone catalysts in the current quarter.